This page contains brief information about abemaciclib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Abemaciclib is approved to treat:
- Breast cancer that is hormone receptor positive (HR+) and HER2 negative(HER2-) and is advanced or has metastasized (spread to other parts of the body).
- It is used with fulvestrant in women whose disease got worse after treatment with hormone therapy.
- It is used alone in women and men whose disease got worse after treatment with hormone therapy and previous chemotherapy given for metastatic disease.
- It is used with an aromatase inhibitor given as first-line hormone therapy in postmenopausal women.
Abemaciclib is also being studied in the treatment of other types of cancer.
More About Abemaciclib
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Abemaciclib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.